Stryker (NYSE:SYK) Sets New 12-Month Low – Here’s Why

Stryker Corporation (NYSE:SYK) reached a new 52-week low on Thursday . The company traded as low as $328.23 and last traded at $338.2070, with a volume of 1622916 shares traded. The stock had previously closed at $345.78.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Citi and some analysts see this as a transitory event and have pointed to near-term catalysts that could drive upside over the next 90 days, suggesting analyst conviction on Stryker’s longer-term outlook remains. Cyberattack Knocks Stryker Stock (SYK) — But Citi Sees Upside with ‘90-Day Catalyst Watch’
• Positive Sentiment: Stryker recently launched its SmartHospital platform to expand digital offerings and drive long-term revenue diversification — a strategic product push that supports growth outside hardware alone. Stryker (SYK) Expands Digital Healthcare Push with New SmartHospital Platform
• Neutral Sentiment: Stryker has confirmed a cybersecurity incident and says it is investigating; the company has been working to restore IT systems and assess operational and patient-safety impacts. Details remain limited and the situation is ongoing. Stryker Investigates Cybersecurity Incident Disrupting IT Systems
• Negative Sentiment: Multiple outlets report that the Iran-linked Handala group claims a destructive “wiper” attack that wiped roughly 200,000+ devices and exfiltrated an estimated 50 TB of data—such claims raise potential regulatory, remediation and reputational costs. Stryker Cyberattack Update: Iran-Linked Handala Group Claims Destructive Wiper Attack on Medical Tech Giant
• Negative Sentiment: Market reaction has been negative: shares dropped several percent on the reports as investors price in operational disruption, potential remediation costs and uncertainty about data loss and downstream impacts. Stryker (SYK) Stock Plunges 3.6% Following Major Cyberattack Claim by Iran-Linked Hackers

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Piper Sandler reissued an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Robert W. Baird set a $437.00 target price on shares of Stryker in a research report on Friday, January 30th. Barclays reiterated an “overweight” rating and issued a $469.00 price target on shares of Stryker in a report on Monday, February 2nd. Wells Fargo & Company increased their price objective on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Finally, BTIG Research lifted their target price on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $428.61.

Stryker Trading Down 1.4%

The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average is $365.70 and its 200-day moving average is $368.30. The company has a market cap of $130.43 billion, a PE ratio of 40.58, a P/E/G ratio of 2.10 and a beta of 0.85.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same period in the previous year, the firm posted $4.01 EPS. The business’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Sankala Group LLC purchased a new stake in Stryker in the 4th quarter worth about $26,000. Clayton Financial Group LLC bought a new position in shares of Stryker during the third quarter valued at approximately $26,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Stryker in the second quarter worth approximately $28,000. Kilter Group LLC bought a new stake in shares of Stryker during the 2nd quarter worth approximately $29,000. Finally, Howard Hughes Medical Institute purchased a new position in Stryker during the 2nd quarter valued at $29,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.